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Introduction
Genotoxic N-nitroso compounds (NOC) are widespread in our diet and the environment. They are found in processed meat and fish, beer, cosmetics and cigarette smoke (Fahrer and Kaina 2013) . Furthermore, NOC are formed endogenously in the stomach and the large intestine by nitrosation of amino acids (Fahrer and Kaina 2013) . These harmful compounds cause DNA alkylation and thereby generate a plethora of DNA adducts, such as N-methylpurines and O 6 -methylguanine (O 6 -MeG) (Fu et al. 2012) . O 6 -MeG is repaired by the suicide enzyme O 6 -methylguanine-DNA methyltransferase (MGMT) in a damage reversal reaction by transferring the methyl group from O 6 -MeG onto a cysteine residue located in its active site (Daniels et al. 2004 ). The Alexander Kraus and Maureen McKeague contributed equally.
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S-methylation of MGMT leads to its inactivation and concomitant degradation by the ubiquitin-proteasome pathway (Xu-Welliver and Pegg 2002) . Interestingly, a number of compounds modulate the MGMT level and its transferase activity. Antioxidants such as N-acetyl cysteine and the polyphenol curcumin were shown to increase MGMT activity (Niture et al. 2007) , whereas the disulfide compound and dietary supplement α-lipoic acid (LA) was identified as a natural MGMT inhibitor (Dörsam and Fahrer 2016; Göder et al. 2015) . Importantly, persistent O 6 -MeG lesions have detrimental biological consequences including mutagenicity and carcinogenicity (Kaina et al. 2007) . Apart from that, O 6 -MeG has also cytotoxic potential due to the downstream generation of DNA double-strand breaks (DSBs) (Mojas et al. 2007; Ochs and Kaina 2000; Quiros et al. 2010) .
NOC-related compounds such as dimethylhydrazine and its metabolite azoxymethane (AOM) are frequently used in rodents to initiate colon carcinogenesis through induction of O 6 -MeG and other alkylated DNA bases (Neufert et al. 2007 ). Alkylating agents also play an important role in cancer chemotherapy due to their induction of cytotoxic DSBs, resulting mainly from subsequent replications over O 6 -MeG. These methylating anticancer drugs include temozolomide (TMZ) and dacarbazine (DTIC), which are both triazine compounds used for the treatment of high-grade glioma and malignant melanoma .
Thus, understanding the basis of O 6 -MeG formation and how its repair is regulated are critical in broad biological questions, ranging from fundamental mechanisms of mutagenesis to creating strategies to overcome clinical resistance to cancer therapeutics. However, gaining a functional and quantitative picture of how much O 6 -MeG is in genomic DNA from cells and tissues remains difficult. Immunological assays for detection of O 6 -MeG have been developed that are based upon a monoclonal antibody against the adduct (Seiler et al. 1993 ). This O 6 -MeG antibody has been used to visualize the DNA lesion in fixed cultured cells and organs, e.g., liver and colon, by immunofluorescence microscopy Seiler et al. 1993 ). In addition, the antibody has been successfully employed for immuno-slot blot (ISB) analysis of O 6 -MeG lesions in genomic DNA extracted from cells and tissue Mikhed et al. 2016; Stephanou et al. 1996) , and an ELISA-related assay, in which single-stranded (ss) DNA fragments with O 6 -MeG were captured by the antibody followed by the detection of the ssDNA (Georgiadis et al. 2011) . Complementary to immunoassay strategies, DNA adducts have been measured in diverse sample matrices by liquid chromatography combined with tandem mass spectrometry (LC-MS/ MS). This approach was successfully used to quantify O 6 -MeG in lung and liver DNA (≥ 50 µg) from rats chronically exposed to 10 ppm of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), which worked with fresh-frozen and formalin-fixed paraffin-embedded tissue (Guo et al. 2016; Upadhyaya et al. 2009) . By means of LC-MS/MS, the formation of O 6 -MeG was also monitored in calf thymus DNA and genomic DNA (100 µg) from colorectal cancer cells challenged in vitro with potassium diazoacetate at mM doses (Vanden Bussche et al. 2012) .
Here, we performed a head-to-head comparison of these methods and examined the scope of each method for measuring O 6 -MeG adducts in both cells and tissues isolated from animals exposed to the anticancer drug TMZ and the colonotropic carcinogen AOM. Our data illustrated that both immunofluorescence (IF) and immuno-slot blot (ISB) assay permitted the time-and dose-dependent detection of O 6 -MeG in CRC cells in a semi-quantitative manner, but are limited in sensitivity as illustrated in colon tissue exposed to low AOM doses. The UPLC-MS/MS approach was demonstrated to be highly sensitive and specific, allowing for the quantification of O 6 -MeG adducts in CRC cells and peripheral blood mononuclear cells (PBMCs) at clinically relevant TMZ doses. Furthermore, the dose-response curve of AOM-induced O 6 -MeG formation was assessed by mass spectrometry in liver and colon tissue of mice differing in their MGMT repair status. Using hockey stick dose-response modeling, our data revealed, for the first time, a genotoxic threshold for O 6 -MeG formation in vivo, resulting from MGMT repair activity.
Materials and methods

Material
All solutions were made with deionized water (18.2 MΩ, resistivity). O 6 -methyl-d 3 -guanine (O 6 -Me-d 3 -G) was from Toronto Research Chemicals (Toronto, Canada). O 6 -MeG, ammonium hydroxide (ACS Reagent 28-30%), hydrochloric acid (ACS Reagent 37%), and acetic acid (HPLC grade) were purchased from Sigma-Aldrich (Buchs, Switzerland). Guanine was obtained from Acros Organics (New Jersey, USA) and Strata-X polymeric columns (30 µm) were from Phenomenex (Torrance, USA). Methanol (HPLC Gradient Grade) was bought at VWR (Dietikon, Switzerland).
Cell culture
HCT116 colorectal cancer cells were kindly provided by Dr. Bert Vogelstein (John Hopkins University, Baltimore, USA). HCT116 cells were cultured in DMEM (Life Technologies, Darmstadt, Germany) supplemented with 10% FCS and antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin). PBMCs (peripheral blood mononuclear cells) were isolated from buffy coat by density centrifugation as described previously (Heylmann and Kaina 2016) . Buffy coat from human healthy donors was provided by the blood transfusion center at University Medical Center, Mainz, Germany. Blood samples were layered on Histopaque (Sigma-Aldrich, Deisenhofen, Germany) and centrifuged at 2500 rpm for 35 min at RT without the brake. PBMCs (lymphocytes, monocytes) were collected, transferred to a 50 ml tube and resuspended in wash buffer (2 mM EDTA in PBS with 0.5% bovine serum albumin). Cells were pelleted by centrifugation and washed three times in wash buffer. Finally, cells were resuspended in X-VIVO 15 medium (Lonza, Basel, Switzerland) and transferred into six well plates.
Animal experiments
Mgmt-null (MGMT −/− ) mice on a C57BL/6 background were described previously (Bugni et al. 2009; Glassner et al. 1999 ). Eight to 14 weeks old MGMT −/− and C57BL/6 wildtype (WT) mice were used. All mouse strains were obtained from the in-house animal breeding facility at University Medical Center, Mainz, Germany. Animal experiments were approved by the government of RhinelandPalatinate and the Animal Care and Use Committee of the University Medical Center, Mainz, Germany. All animal studies were performed in agreement with the German federal law and the guidelines for the protection of animals. Azoxymethane (AOM; Sigma, Deisenhofen, Germany) solution was prepared as described previously and administered by intraperitoneal injection at doses up to 10 mg/kg body weight (bw) . Animals were then sacrificed after 24 h. Colon and liver tissues were harvested, carefully rinsed with ice-cold PBS and either snap-frozen in liquid nitrogen or fixed in 4% neutral-buffered formaldehyde solution (Roti®-Histofix; Carl Roth, Karlsruhe, Germany). For subsequent histological analysis, fixed tissue was embedded in paraffin and stored at room temperature awaiting immunological analysis as detailed below.
Immunofluorescence detection of O 6 -MeG adducts HCT116 cells (2 × 10 5 cells per well) were seeded onto cover slips and allowed to adhere overnight. The medium was replaced by fresh medium and the cells were then pre-incubated with the specific MGMT inhibitor O 6 -benzylguanine (O 6 -BG; 10 µM; Sigma-Aldrich, Deisenhofen, Germany) for 2 h. Temozolomide (TMZ; kind gift of Dr. Geoffrey P. Margison, Manchester, UK) was added (0 to 1000 µM) and cells were incubated for another 2 h. Following aspiration of the medium, cells were washed with pre-warmed phosphatebuffered saline (PBS) and fixed with ice-cold methanol for 15 min at − 20 °C. After two washing steps with PBS, RNA was digested with a mixture of RNase A (200 µg/ml) and RNase T (50 U/ml) for 10 min at 37 °C. Cells were washed with PBS followed by Proteinase K (20 µg/ml) digestion for 10 min at 37 °C. Cells then were washed with 0.2% glycine in PBS for 10 min and cover slips were transferred into a humid chamber. Unspecific binding sites were blocked with 5% BSA in PBS for 45 min at RT. Subsequently, the samples were incubated with a primary mouse antibody against O 6 -MeG (diluted 1:2000 in 1% BSA in tris-buffered salinetween 20 (TBS-T); #SQX-SQM003.1, Axxora, Farmingdale, USA) overnight at 4 °C. After several washing steps with TBS-T and PBS, the samples were incubated with an appropriate secondary antibody (Goat-anti-Mouse-Alexa Fluor 488, diluted 1:400 in 1% BSA/PBS, Life Technologies) for 2 h at RT under light exclusion. After several washing steps with TBS-T and PBS, the nuclei were counterstained with TO-PRO-3 (diluted 1:100 in PBS, Life Technologies, Darmstadt, Germany) for 15 min at RT. Finally, the cover slips were coated with Vectashield® (Linaris, Dossenheim, Germany) medium and transferred onto a microscope slide. The samples were analyzed by confocal microscopy with a Zeiss Axio Observer.Z1 microscope equipped with a LSM710 laser-scanning unit (Zeiss, Oberkochen, Germany). Images were acquired with ZEN software and processed with ImageJ (NIH, USA). The mean O 6 -MeG intensity per nucleus was assessed with ImageJ (at least ten sections with 100 nuclei/treatment, n ≥ 3) and data were evaluated using GraphPad Prism 7.0 software.
Isolation of genomic DNA from cells and tissue
HCT116 cells (4 × 10 6 ) were seeded into 10 cm dishes and grown overnight. Cells were then incubated in fresh medium and O 6 -BG was added as described above. After 2 h, cells were treated with increasing doses of TMZ as indicated and harvested. To extract the genomic DNA, cells were resuspended in 300 µl Tris-EDTA buffer supplemented with 0.1% Triton X-100 and RNase A (30 µg/ml). After incubation for 1.5 h at RT, proteinase K (20 µg/ml) and 1% SDS were added and incubated overnight at 48 °C. In the next step, 700 µl phenol/chloroform/isoamyl alcohol (Carl Roth, Karlsruhe, Germany) was added. The samples were briefly vortexed and centrifuged for 5 min at 20,000g. The upper aqueous layer was transferred into a new reaction tube and extracted again with 700 µl phenol/chloroform/isoamyl alcohol. Following centrifugation, the upper aqueous layer was transferred to a new reaction tube and supplemented with 750 µl 90% ethanol and 1 M NH 4 OAc to precipitate the DNA for 1 h at 4 °C. The samples were then centrifuged for 45 min at 20,000g and 4 °C. The supernatant was discarded and the DNA pellets were washed with 1 ml 70% EtOH. Following centrifugation at 20,000g and 4 °C for 15 min, the supernatant was discarded and the remaining DNA pellets were dissolved in 50-100 µl TE buffer. The samples were gently vortexed and put on ice. Finally, the DNA content 1 3 and purity were determined with a NanoDrop 2000 (Thermo Scientific, Dreieich, Germany).
PBMCs (6 × 10 6 ; approximately 70% T-lymphocytes) in 2.5 ml X-Vivo 15 medium were exposed to increasing doses of TMZ (50 to 1000 µM) for 2 h at 37 °C. PBMCs were then transferred into tubes, washed with PBS and centrifuged for 5 min at 300g. The supernatant was discarded and the pellets were resuspended in PBS. The cell suspension was centrifuged at 600g for 5 min and pellets were processed to isolate genomic DNA as described above.
To isolate genomic DNA from mouse tissue, snap-frozen colon and liver (~ 20 mg) were homogenized with a pestle and samples were processed as described above.
Immuno-slot blot assay (ISB) of O
-MeG adducts
A previously established immuno-slot blot assay (Göder et al. 2015 ) was used to determine O 6 -MeG adduct levels in genomic DNA extracted from TMZ-treated HCT116 cells or AOM-treated animals. First, 500 ng DNA in TE buffer was denatured by heating for 10 min at 99 °C. 50 µl of 2 M ammonium acetate were then added and samples were vortexed followed by their immediate vacuum aspiration onto a positively charged nylon membrane (GE Healthcare, Munich, Germany). The membrane was fixed for 90 min at 90 °C and incubated for 60 min with blocking buffer (5% dry milk in TBS-T). Subsequently, the membrane was incubated with a primary mouse antibody against O 6 -MeG (diluted 1:500 in 1% BSA in TBS-T) overnight at 4 °C. After several washing steps with TBS-T, the membrane was incubated with a secondary peroxidase-coupled antibody (G-α-M-HRP, diluted 1:2000 in blocking buffer; Santa Cruz Biotechnology, Heidelberg, Germany) for 1 h at RT. After several washing steps with TBS-T, O 6 -MeG adducts were visualized by enhanced chemoluminescence detection using Western Lightning® Plus-ECL (Perkin Elmer, Rodgau, Germany). Densitometric evaluation of blots was conducted by Adobe Photoshop CS5 and analyzed by GraphPad Prism 7.0 software.
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded (FFPE) colon and liver tissues from AOM-treated mice were sectioned at 5 µm and processed for immunohistochemistry as reported . Tissue sections were incubated at 60 °C for 30 min in a drying oven, then deparaffinized in xylene and rinsed in graded ethanol solutions. Following several washing steps, the sections were immersed in pre-heated antigen retrieval solution (DAKO, Hamburg, Germany) for 30 min in a steamer. The samples were allowed to cool for 15 min at RT and washed several times in PBS. This process was followed by a permeabilization step in 0.4% Triton X-100 in PBS for 5 min at RT. Sections were then rinsed in PBS and RNA digestion was performed for 1 h at 37 °C using both RNase A (200 µg/ml) and RNase T (50 U/ml).
After alkaline unwinding of the DNA for 5 min, the sections were carefully washed in PBS and incubated with pepsin (60 µg/ml) 30 min at 37 °C. Thereafter, the sections were washed with PBS and incubated with proteinase K (20 µg/ ml) for 30 min at 37 °C. Following another washing step with 0.2% glycine-PBS, the sections were incubated for 2 h with blocking solution (DAKO, Hamburg, Germany) at RT. The sections were then treated with an O 6 -MeG antibody (1:100, diluted in 2% BSA in PBS) overnight at 4 °C. After several washing steps in PBS-0.1% Tween, the samples were incubated with the appropriate secondary antibody (G-α-M-Alexa 488, 1:500 diluted in 2% BSA in PBS/0.2% Triton X-100; Life Technologies, Darmstadt, Germany) for 2 h at RT. The sections were then rinsed thoroughly with PBS-0.1% Tween and a nuclear staining was performed using TO-PRO-3 (1:100 in PBS) for 30 min at RT.Slides were mounted with Vectashield® medium and analyzed by confocal microscopy with a Zeiss Axio Observer.Z1 microscope equipped with a LSM710 laser-scanning unit (Zeiss, Oberkochen, Germany). Images were processed with ImageJ version 1.45 (NIH, USA).
LC-MS/MS analysis of O
-MeG adducts
DNA hydrolysis
All DNA samples were measured on a Nanodrop 1000 (PeqLab, Rodgau, Germany). The total number of nucleotides present was calculated based on the average base pair molecular weight of 650 g/mol. The number of guanine residues was calculated assuming 21% guanine in the mouse genome, and 20.5% in the human genome (Ruvinsky and Graves 2005) . A minimum of 10 µg of DNA was transferred to new Eppendorf DNA LoBind microcentrifuge tubes and concentrated to dryness by vacuum centrifugation. Samples were resuspended and thoroughly vortexed in 500 µL of a 0.1 M HCl solution spiked with 2 nM of the internal standard (IS), O 6 -Me-d 3 -G. To release the purines from the DNA, each sample was heated for 2 h at 70 °C. Samples were cooled at RT for at least 10 min followed by a 20 s centrifugation pulse at 1000g. Each sample was neutralized with 15 µL of 15% aqueous ammonium hydroxide (NH 4 OH) and vortexed.
Confirmation of DNA hydrolysis
30 µL from each DNA sample was removed for HPLC analysis to verify complete release of guanine. Quantification of guanine was carried out on an Agilent Technologies 1200 Series HPLC (Santa Clara, CA) with a UV-visible detector.
The method was adapted from Roy et al. (2013) . To monitor absorbance, the diode array detector was set to 270 nm and the reference was set to 360 nm.
Chromatography was performed with a Luna C18 Column (5 µm, 100 Å, 4.6 × 250 mm) from Phenomenex (Torrance, CA). Mobile phase A was water and mobile phase B was methanol. The flow rate was 1 mL/min and the column temperature was not controlled. 8 uL of sample was injected and separated as follows: 1% B for 3 min, 1-10% B linear gradient for 7 min, a wash at 85% B for 3 min, and re-equilibration at 1% B for 7 min (20 min total run time). Guanine eluted at a retention time of 8.7 min. Samples were analyzed in duplicate.
A calibration curve for guanine (2-100 µM) was prepared in a 0.1 M HCl, 0.03% NH 4 OH solution. The amount of guanine in each sample was calculated on the basis of guanine peak area, slope of the calibration curve, and fraction of the total volume injected. The percent recovery of guanine was calculated using the guanine measured by HPLC compared to the theoretical amount calculated from the Nanodrop measurement. All samples yielded between 80-120% recovery of released guanine.
Adduct enrichment
Solid phase extraction (SPE) columns (Strata-X 33 µm, 30 mg/1 mL) were preconditioned with two 1 mL washes with methanol, followed by three separate washes of 1 mL water each. The entire remaining sample (485 µL) was loaded onto a column for enrichment and purification. Each column was then washed with 600 µL water, then 600 µL of 3% methanol. Elution was performed by adding 600 µL of 60% methanol. The entire eluent was recovered and vacuum centrifuged to dryness in 250 µL conical glass HPLC inserts. Samples were stored at − 20 °C. Immediately prior to LC-MS/MS analysis, samples were thawed, reconstituted in 20 µL water, and sonicated for 10 min.
LC-ESI-MS/MS
Samples were analyzed by LC-MS/MS using a nanoAcquity UPLC system (Waters, Milford, CA) and Agilent tandem quadrupole mass spectrometer (LCQ Vantage, Thermo Scientific, Waltham, MA) with an electrospray ionization source (ESI). Mass spectrometry ionization parameters were optimized by tuning the instrument with 1 µM O 6 -MeG, O 6 -d3-MeG, and G by direct injection. The ESI source was set in positive ion mode with the following parameters: capillary temperature, 270 °C; spray voltage, 3000 V; sheath gas pressure, 25; ion sweep gas pressure, 0; aux gas pressure, 5; Q2 CID gas pressure, 1.5 mTorr; collision gas, argon; scan width, m/z 0.01; scan time, 0.1 s. Optimal collision energies for each transition are in Table 1 .
Chromatography was performed with a Synergi 4 µm Polar-RP column (Phenomenex 80 Å 150 × 0.5 mm). Mobile phases were sonicated for 15 min prior to the run. Mobile phase A was water with 0.05% acetic acid, phase B was methanol, and the flow rate was 10 µL/min at the column temperature was set to 40 °C. The autosampler was cooled to 4 °C, a seal wash was performed every 30 min, and the injection volume was 1 µL. Samples were separated as follows: 0% B for 1 min, 1-40% B gradient for 14 min, 99% B for 5 min, and re-equilibrate for 15 min. The eluent was directed to the MS between 2 min and 14 min, otherwise the eluent was diverted to the waste. O 6 -MeG and O 6 -d3-MeG eluted at 9.8 min. The single reaction monitoring (SRM) transitions that were monitored are listed in Table 1 . Xcalibur software (Thermo) was used for data acquisition and processing.
Calibration curves
A series of eight different O 6 -MeG standards of known concentration (0.5, 1, 2.5, 5, 10, 25, 40, 50 nM) was prepared. A fresh 20 µL aliquot of each prepared standard was concentrated to dryness by vacuum centrifugation and resuspended in 500 µL of a 0.1 M HCl solution spiked with 2 nM of the IS as above. Thermal acid hydrolysis and SPE were performed in the same way as the DNA samples. Standards were reconstituted with 20 µL water for LC-MS/MS analysis. Each calibrated standard was measured in triplicate. Standards were prepared and analyzed immediately prior to analysis. The peak area ratio was determined for each standard by dividing the peak area of the standard by the peak area of the IS. Data were fitted to a straight line by least squares (ordinary) in GraphPad Prism 7.0.
Adduct quantification
Each sample was first injected once into the MS to ensure they were within the linear range. For samples that were higher than the standard curve, a 1:10 dilution was performed in water. For samples where the O 6 -MeG was lower than the standard curve, the injection volume was increased to 4 µL or was analyzed using a nanoAcquity UPLC M-class system (Waters, Milford, CA) and tandem quadrupole mass spectrometer (TSQ Quantiva, Thermo Scientific, Waltham, MA) with an electrospray ionization source (ESI) using the same ionization parameters and chromatography. Relative standard deviation of the technical triplicates was less than 20%. The peak area ratio was determined for each sample by dividing the peak area for O 6 -MeG by the peak area for O 6 -d3-MeG. The amount of O 6 -MeG in each sample was calculated on the basis of the peak area ratio, the slope of the calibration curve, and the fraction of the total volume injected. Adduct levels are reported as adducts per 10 7 total nucleotides.
Statistics
Experiments were performed independently three times, unless otherwise stated. Figures show representative images. Values are depicted as mean ± standard errors of the mean (SEM) using GraphPad Prism 7.0 Software.Statistical analysis was performed using two-sided Student's t test and statistical significance was defined as p < 0.05.
Hockey stick dose-response modeling
Dose-response modeling was performed as described (Lutz and Lutz 2009 ) using R software (version 3.3.1) (R Development Core Team 2013). The lower confidence interval of the threshold dose is also reported. It should be noted that confidence intervals of < 0 lacks statistical significance for a threshold.
Results
In this study, levels of O 6 -MeG resulting from exposure to either the anticancer drug TMZ or the colonotropic carcinogen AOM were evaluated in CRC cells and different murine tissues (i.e., liver and colon) by a combination of qualitative immunological assays and quantitative mass spectrometry (Fig. 1a) . AOM requires metabolic activation by the hepatic enzyme CYP2E1 to generate a reactive methylating agent (Neufert et al. 2007) . TMZ, on the other hand, spontaneously decomposes at neutral pH to deliver a methyl group (Zhang et al. 2012 ). Both chemicals give rise to DNA reactive 
Time-dependent formation of O 6 -MeG in cells challenged with TMZ
First, we investigated the induction and persistence of O 6 -MeG in a time-dependent manner over 24 h. To this end, HCT116 CRC cells were pre-incubated with O 6 -BG for 2 h to inactivate MGMT and then challenged with TMZ for up to 24 h. Confocal IF microscopy showed a timedependent formation of O 6 -MeG with a peak after 4 h, which persisted up to 14 h after exposure to TMZ (Fig. 2a,  b) . After 24 h, the O 6 -MeG level declined, presumably because of resynthesis of MGMT or lesion dilution resulting from cell division. To quantify the adducts, we used stable isotope dilution mass spectrometry. The results showed a similar time course of O 6 -MeG accumulation as compared to the IF analysis (Fig. 2c) . 4 h after treatment with 500 µM TMZ, the basal O 6 -MeG level (~ 2 lesions per 10 7 nucleotides) increased to 116 O 6 -MeG adducts per 10 7 nucleotides. After 24 h, the O 6 -MeG content decreased to 58 adducts per 10 7 nucleotides, which is still considerably higher than in untreated control cells. Representative chromatograms for O 6 -MeG measurements in TMZ-treated HCT116 cells are also shown (SI, Fig. 1 ). To illustrate the intrinsic MGMT repair capacity in HCT116 cells, cells were incubated in the absence or presence of the MGMT inhibitor O 6 -BG and challenged with 500 µM TMZ (Fig. 2d) . Mass spectrometry revealed a slightly higher, yet not statistically significant O 6 -MeG level following TMZ treatment in cells pre-treated with the MGMT inhibitor (74 versus 56 adducts per 10 7 nucleotides), indicating the protection mediated by MGMT against TMZinduced O 6 -MeG in HCT116 cells. 
-MeG in cells challenged with TMZ
To monitor the dose-dependent formation of O 6 -MeG adducts, HCT116 cells were pre-incubated with the pharmacological inhibitor O 6 -BG to block MGMT activity. The cells were then exposed to increasing doses of TMZ (0-1000 µM) for 2 h, fixed and processed. O 6 -MeG was specifically labeled with an antibody followed by confocal microscopy (Fig. 3) . As expected, O 6 -MeG displayed exclusive nuclear localization. TMZ, at 100 µM, caused a moderate, significant rise in the O 6 -MeG level relative to the untreated control (Fig. 3a-c) . At higher dose levels, O 6 -MeG levels increased dose dependently (Fig. 3a-c) . Subsequently, we compared the sensitivity of the ISB assay with mass spectrometry-based analysis of O 6 -MeG adducts in genomic DNA from TMZ-treated HCT116 cells. By means of the ISB assay, we were able to detect a dose-dependent O 6 -MeG DNA adduct formation, reaching statistical significance only at doses ≥ 500 µM TMZ (Fig. 4a, b) . Doses up to 250 µM were hardly distinguishable from the background level (Fig. 4b) . In contrast, UPLC-MS/MS revealed a significant rise in O 6 -MeG at a lower dose of 100 µM TMZ with 13 adducts per 10 7 nucleotides, while the baseline level without TMZ treatment was low (2.5 adducts per 10 7 nucleotides) (Fig. 4c) . This clearly demonstrates the higher sensitivity and specificity of the mass spectrometry-based approach. It is interesting to note that we were also able to measure O 6 -MeG in PBMC following in vitro treatment with 100 µM TMZ (SI Table 1 ). This experiment was conducted without the MGMT inhibitor O 6 -BG, i.e., in the presence of intrinsic MGMT repair activity. 
Assessment of O
-MeG in tissue of AOM-treated mice and impact of MGMT
Having extensively characterized the dose-and timedependent formation of O 6 -MeG in CRC cells, we switched to a mouse model using B6/J wildtype (WT) and transgenic, MGMT-deficient mice (MGMT −/− ). The animals were exposed to AOM, which is a well-established colonotropic carcinogen. AOM requires metabolic activation in the liver and the colorectum, involving an interplay of hepatic cytochrome P450 2E1 (CYP2E1)-and UDPglucuronosyl-transferase (UGT)-dependent metabolism together with ß-glucuronidase activity from gut bacteria (Neufert et al. 2007 ). AOM was administered by intraperitoneal injection in doses ranging from 0 to 10 mg/ kg bw and animals were sacrificed after 24 h to isolate genomic DNA from liver and colorectal tissue. O 6 -MeG levels were already assessed in our previous work using the ISB technique . Both genotypes displayed a dose-dependent formation of hepatic O 6 -MeG adducts, with significant higher levels in MGMT knockout mice that lack methyl transferase activity towards O 6 -MeG . In colorectal tissue, no differences in O 6 -MeG levels were detected in WT mice challenged with up to 10 mg/kg AOM, while a dose-dependent increase was observed in MGMT-deficient mice using the ISB assay (SI Fig. 2a, b) . Next, the liver samples were analyzed by mass spectrometry, resulting in dose-dependent generation of O 6 -MeG as a function of the repair phenotype (Fig. 5a , c). It should be stressed that O 6 -MeG levels were about twofold higher in MGMT −/− as compared to WT animals at doses of 3 and 5 mg AOM/kg bw (SI Fig. 3a) , reaching statistical significance only for 5 mg. Finally, we studied O 6 -MeG formation in colorectal tissue, which is pivotal for DNA alkylation-triggered colorectal carcinogenesis. Intriguingly, UPLC-MS/MS revealed O 6 -MeG induction (6 adducts per 10 7 nucleotides) at the lowest tested AOM dose (3 mg AOM/kg bw) in WT animals, which was tremendously augmented (60 adducts per 10 7 nucleotides) at the highest AOM dose (10 mg/kg bw) (Fig. 5e) . In stark contrast, MGMT −/− animals displayed a dose-dependent and almost linear formation of O 6 -MeG adducts (16, 35, 81 adducts per 10 7 nucleotides, respectively) (Fig. 5g) . Side-by-side comparison of the induced O 6 -MeG lesions in colorectal tissue showed significantly higher levels in MGMT −/− versus WT animals at AOM doses ≤ 5 mg/kg bw (SI Fig. 3b ).
Dose-response modeling of O
-MeG adducts and threshold analysis
We performed hockey stick dose-response modeling (Lutz and Lutz 2009 ) on the in vivo data following ISB and MS quantification of O 6− MeG adducts to identify a potential threshold dose and assess the dose-response relationship (Fig. 5b, d, f, h) . We only identified a threshold dose using UPLC-MS/MS quantification, but not via ISB (SI Fig. 4) . Interestingly, the threshold dose of 1.9 mg/kg bw and 4.8 mg/kg bw AOM in the respective liver and colon of WT mice was absent in the MGMT-deficient genotype (Table 2) , indicating a change in dose-response relationship from sub-linear to linear when MGMT-mediated repair of O 6 -MeG is lacking. -BG) for 2 h and then challenged with increasing doses of the anticancer drug TMZ (0-1000 µM) for additional 2 h. O 6 -MeG adducts were determined in isolated genomic DNA by an immune slot blot approach. Data are depicted as mean + SEM (n = 3). ***, p < 0.001; *, p < 0.05; ns not significant. b Representative immunoslot blot c Cells were treated as described in a and genomic DNA was isolated. The number of O 6 -MeG lesions per 10 7 nucleotides (nts) was obtained by mass spectrometry. Data are given as mean + SEM (n = 3). ****, p < 0.0001; ***, p < 0.001; **, p < 0.005; *, p < 0.05
Discussion
The present work provides a characterisation of currently available techniques to detect and quantify O 6 -MeG adducts in cells and murine tissues, with a focus on their sensitivity and specificity. Furthermore, the approaches were applied to determine genotoxic thresholds using the hockey stick dose-response modeling. First, we showed that IF microscopy allows for the time-and dose-dependent detection of O 6 -MeG in cells treated with the methylating antineoplastic drug TMZ. The procedure itself is relatively fast and not expensive, but includes critical steps such as the unwinding of DNA at alkaline pH, during which the cells can detach. Furthermore, the O 6 -MeG antibody caused some background signal, which is particularly prominent in tissue samples (SI Fig. 5 ). The digestion of proteins and RNA are further essential steps to yield specific, nuclear staining of O 6 -MeG. This method has been employed to detect O 6 -MeG in cells and in tissue, particularly liver and colon tissues Nyskohus et al. 2013) , as it offers the advantage to visualize damage induction in distinct cell types and regions within a given tissue. Using confocal microscopy, we could demonstrate the spatial formation of O 6 -MeG adducts in liver lobuli, with the highest damage induction in hepatocytes around the central hepatic vein, while no adducts were formed in the periportal field [SI Fig. 5 and (Fahrer et al. 2015) ]. Interestingly, O 6 -MeG staining can also be combined with the detection of γH2AX, an established marker for DNA DSBs (Fahrer et al. 2014 ; Kinner et al. 2008) , in paraffin-embedded liver tissue . The IF-based method proved also to be useful for monitoring the time-dependent induction and removal of O 6 -MeG adducts in colon crypts of rats treated with up to 15 mg AOM/kg bw (Nyskohus et al. 2013) . However, IF is a semi-quantitative method and offers moderate sensitivity as compared to mass spectrometry, which was revealed mainly during the analysis of tissue samples. For example, our UPLC-MS/MS approach detected O 6 -MeG in liver tissue of WT mice at low AOM doses (Fig. 5) , whereas IF microscopy did not .
Second, we employed the ISB assay to detect O 6 -MeG adducts in genomic DNA isolated from cells and tissues exposed to methylating agents. The ISB assay allows for the direct comparison of multiple samples (up to 48) on the same membrane, requiring only a little amount of DNA (≤ 500 ng). Furthermore, it is a very fast and inexpensive method. We showed a dose-dependent O 6 -MeG generation in cells challenged with TMZ, however with only moderate sensitivity. Nevertheless, O 6 -MeG adducts were monitored in liver DNA form WT and MGMT-deficient mice exposed to low dose levels of AOM (3 mg/kg bw). It also should be mentioned that the effect of the different DNA repair phenotype, i.e., MGMT proficiency and MGMT deficiency, was clearly visible here. In support of its rather moderate sensitivity, no AOM-dependent formation of O 6 -MeG was detectable in DNA isolated from colorectal tissue of WT animals using the ISB assay (SI Fig. 2) . The method has also been applied to measure O 6 -MeG and O 6 -ethylguanine in human lymphocytes exposed to methylnitrosurea (MNU) and ethylnitrosurea (ENU), respectively, at the mM dose range (0.5-4 mM) in vitro (Jiao et al. 2007; Stephanou et al. 1996) , confirming the limited sensitivity of ISB. This drawback is also attributable to the background signal, which is observed in untreated control samples.
Third, we applied UPLC-MS/MS to quantify O 6 -MeG adduct levels in human cells and murine tissue samples (liver and colon). This approach was highly sensitive and superior to the other antibody-based methods (IF and ISB) throughout our experiments. While former studies using HPLC-MS/MS required moderate to high amounts of DNA (50 µg up to 1 mg) (Upadhyaya et al. 2009; Vanden Bussche et al. 2012; Zhang et al. 2006) , we have optimized the sample cleanup and subsequent analysis, reducing the amount of DNA needed to below 10 µg. Our UPLC-MS/MS approach is highly sensitive and permitted the detection of O 6 -MeG in colorectal tissue of WT mice challenged with only 3 mg/kg bw AOM. This method was also instrumental for our very recent study dealing with the impact of the DNA repair protein PARP-1 on alkylation-induced colorectal carcinogenesis (Dörsam et al. 2018) .
Mass spectrometry revealed moderate differences in O 6 -MeG levels following TMZ treatment in the presence or absence of the MGMT inhibitor O 6 -BG, which were however not statistically significant. This finding could be attributable to several factors. First, HCT116 cells display only moderate MGMT activity (Göder et al. 2015) , whereas other CRC cells such as HT29 have a fourfold higher MGMT activity (Tomaszowski et al. 2015) . Less O 6 -BG is thus required to inhibit the cellular MGMT pool in HCT116 cells, attenuating the effects particularly at a high TMZ dose of 500 µM. Second, it is conceivable that the catalytic Cys residue of MGMT is directly alkylated by TMZ, which could also overshadow the O 6 -BG-mediated inhibition. In support of this notion, a previous study indicated that the S N 2 alkylating agent methyliodide and, at higher doses, the S N 1 alkylating agent MNU directly alkylate MGMT in cell extracts (Oh et al. 1996) . Third, the TMZ exposure time used for this experiment (2 h) might be not ideal, bearing in mind that O 6 -MeG induction by TMZ peaks after 4 h (Fig. 2c) .
Intriguingly, our measurements revealed a linear, dosedependent accumulation of adducts in MGMT-deficient mice, whereas adduct levels exhibited non-linearity in WT animals, and the threshold analysis supports this result (Table 2) . We found threshold doses of AOM in the liver and colon of treated mice at 1.93 mg/kg bw and 4.78 mg/kg bw, respectively. The liver has higher basal levels of the AOM activating enzyme, CYP2E1, than in the colon (Rosenberg and Mankowski 1994) . We could therefore hypothesize that more AOM is activated in the liver and able to react with DNA, accounting for the lower threshold dose than in the colon. Caution is urged however, as the dose-responses look sub-linear (due to vastly higher adduct levels at the highest dose) as opposed to threshold, particularly in the colon (Fig. 5) . However, the difference in threshold dose between the repair phenotypes is intriguing and supports a mechanistic basis for the observed threshold doses Thomas et al. 2013) .
Moreover, it is hypothesized that detoxifying processes can prevent genotoxin activation, subsequent DNA reaction and adduct formation and, therefore, contribute to a nonlinear DNA adduct relationship (Thomas et al. 2015) . The half-life of the DNA adducts (governed by their removal by repair enzymes, such as MGMT) may influence the relationship observed depending on the time following treatment when the adducts were quantified. The influence of DNA repair is evidenced in the absence of threshold doses in the MGMT-deficient phenotype. While this data is limited and firm conclusions on the dose-responses are difficult to draw, it is interesting to speculate particularly, as in this instance, the relationships correlate to our mechanistic understanding of DNA damage induction and repair. This is consistent with our previous study dealing with the impact of DNA repair on the dose-response relationship in alkylation-induced colorectal carcinogenesis and illustrates that initial DNA adduct levels may be correlated with later onset of tumorigenesis.
Using this mass spectrometry-based approach, O 6 -MeG formation was also quantitatively assessed in PBMCs isolated from healthy human volunteers following in vitro treatment with the anticancer drug TMZ. This experiment was conducted without the MGMT inhibitor O 6 -BG, i.e., in the presence of intrinsic MGMT activity that amounts to about 105 fmol/10 6 PBMCs (Janssen et al. 2001) . Interestingly, significant levels of O 6 -MeG were detected at a dose of 100 µM TMZ, which is comparable to the plasma concentration that can be achieved in patients after oral administration of the drug (Britten et al. 1999; Hammond et al. 1999) . It can be envisioned that O 6 -MeG induced by methylating anticancer drugs such as TMZ and DTIC could be monitored in peripheral blood cells as clinical pharmacodynamic biomarker in the future, comparable to γH2AX and poly(ADPribose) as proposed elsewhere (Redon et al. 2010 ). This will assist in stratifying patients and monitoring therapeutic efficacy in personalized medicine, an approach that is also amenable to other DNA-damaging anticancer drugs, including cisplatin and cyclophosphamide (Stornetta et al. 2017) . The advantages and disadvantages of each method used here are summarized in Table 3 .
Very recently, novel strategies have been developed to detect O 6 -MeG in a sequence-specific context. To this end, artifical nucleotides (benzimidazole-derived 2′-deoxynucleoside-5′-O-triphosphates) have been synthesized, which are incorporated into DNA opposite O 6 -MeG by an engineered KlenTaq DNA polymerase (Wyss et al. 2016; Betz et al. 2017) . Novel hybridization probes based on an oligonucleotide with nucleoside analogues conjugated to gold nanoparticles have also been used to successfully detect O 6 -MeG within a mutational hotspot in the KRAS oncogene (Trantakis et al. 2016 ). These chemical approaches may open a new avenue to measure O 6 -MeG levels in a sequencespecific manner at single base resolution instead of assessing the global O 6 -MeG load in genomic DNA. In summary, the UPLC-MS/MS approach allowed for the quantitative, sensitive and specific detection of critical O 6 -MeG adducts in cells and tissue. This technique was further pivotal for the determination of threshold levels for O 6 -MeG adducts, which were caused by the repair enzyme MGMT. We envision that this method will be instrumental to monitor the therapeutic efficacy of alkylating anticancer drugs and to assess dietary and environmental exposure to O 6 -MeGinducing agents. 
